O'Brien Wealth Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

O'Brien Wealth Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-40	Closed	-$16K	–	168
2018 Q3	$16K	Buy	+40	New	+$15.2K	0.01%	113
2018 Q2	–	Sell	-40	Closed	-$14K	–	162
2018 Q1	$14K	Buy	+40	New	+$13.9K	0.01%	104

Other funds holding REGN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

O'Brien Wealth Partners's REGN Position: Q4 2018 in Review

O'Brien Wealth Partners sold out of Regeneron Pharmaceuticals (REGN) in Q4 2018, closing a stake of 40 shares — an estimated $16K sold.

O'Brien Wealth Partners first reported a position in REGN in Q1 2018 and held it in 2 quarters. The position peaked at $16K in Q3 2018. 671 funds tracked by Wall St. Rank hold REGN as of Q4 2018.

O'Brien Wealth Partners reported no remaining Regeneron Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
O'Brien Wealth Partners sold 40 Regeneron Pharmaceuticals shares in Q4 2018, an estimated $16K.
O'Brien Wealth Partners first reported a position in Regeneron Pharmaceuticals in Q1 2018 and held it in 2 quarters.
O'Brien Wealth Partners's Regeneron Pharmaceuticals position peaked at $16K in Q3 2018.
671 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2018.

Based on O'Brien Wealth Partners's 13F filing for Q4 2018, filed 17 Jan 2019.